Delaware
|
0-32353
|
84-1475642
|
(State
or other jurisdiction of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR
240.13e-4(c))
|
|
|
ZIOPHARM
Oncology, Inc.:
|
|
|
(Registrant)
|
|
|
|
By:
|
/s/
Richard E. Bagley
|
|
|
Name:
|
Richard
E. Bagley
|
|
Title:
|
President,
Chief Operating Officer and Chief
Financial
Officer
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated July 31, 2008.
|